Joe Biden, AP Images
April 26, 2021 09:04 AM EDTUpdated 04:43 PM
Pharma
FDA+

Biden signs two bills to clar­i­fy new chem­i­cal en­ti­ties, ed­u­cate on biosim­i­lars

Zachary Brennan

Senior Editor

Pres­i­dent Joe Biden on Fri­day signed in­to law two FDA-re­lat­ed bills, in­clud­ing one to stop drug­mak­ers from win­ning ex­clu­siv­i­ty for drugs that aren’t re­al­ly new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

New CBER chief Prasad is ready­ing 'mas­sive frame­work' around vac­cines, Makary says

Eli Lil­ly turns to South Ko­re­an RNA edit­ing biotech for hear­ing loss in deal worth $1.3B

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

A service from the Financial Times